Sat, Jul 12, 2014, 1:44 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Immune Response Corp. (IMNR) Message Board

  • ShaharAvi ShaharAvi Apr 18, 1998 9:45 AM Flag

    My 2 cents

    I, like everyone else, greatly appreciate both the scientifically- oriented contributions made by so many and the well-reasoned bearish points of view that are presented from time to time.

    Frankly, in regards to Remune's Ph3 Remune trial, the recent angst contains absolutely no new news. I posted several weeks
    ago about my conversation with Larry Gibson. He was quite clear about two things: 1) It was unlikely that the trial would be
    halted early by the DSMB 2) If Remune hit their endpoints in 3/99, there is no doubt that it is approvable given the a priori
    cooperation/input the FDA had in the trial design. Too, I have posted more than once about the false hope that seems to be built into the next
    release from the DSMB.

    Personally, my record as a market predictor is pretty poor. I have no idea what effect on IMNR's stock price there will be
    if the trial is not halted. From what I've read - in both IMNR press releases, analyst reports and media articles, everyone
    expects a 1999 launch of Remune. This is consistent with the trial continuing to 3/99 as the NDA would be filed very soon after and
    the drug approved in less than 6 months - typical of the AIDS drugs that have been approved. So, given the lack of analyst
    coverage on IMNR, I really don't think too many people are holding out for early approval. I do agree (and have stated previously) if
    IMNR does take a significant hit in price, that would represent the "last great fire sale" on IMNR.

    I've been burned before trying to time too finely (see my post on IPIC re: GLIA). I would suggest that those afraid of
    taking a huge hit in May/June should sell a portion of their holdings, not all. As I've mentioned a few times on other boards, even
    if Remune were halted early and the stock price went up big-time, IMNR would STILL likely be substantially undervalued. Hence,
    investors could get in then, with substantial profits ahead w/o most of the perceived risk. So, I'd recommend that people who are
    concerned about IMNR volatility simply hedge their position.


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.